How do mutations in contractile proteins cause the primary familial cardiomyopathies?

Area of Science:

• Cardiovascular Biology
• Molecular Cardiology
• Genetic Heart Diseases

Background:

• Cardiac muscle contractile function is regulated by calcium (Ca2+) and protein kinase A (PKA) phosphorylation.
• Mutations in contractile protein genes cause hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM).
• Understanding the molecular basis of these cardiomyopathies is crucial for explaining disease phenotypes.

Purpose of the Study:

• To assess the functional effects of contractile protein mutations causing HCM and DCM.
• To elucidate the molecular mechanisms underlying HCM and DCM phenotypes.
• To identify patterns in mutation effects on cardiac muscle function.

Main Methods:

• Review and analysis of available evidence on contractile protein mutations.
• Investigation of mutations in physiologically relevant systems.
• Application of a range of experimental techniques to study mutation effects.

Main Results:

• HCM-associated mutations consistently increase myofibrillar Ca2+-sensitivity, though the link to hypertrophy remains unclear.
• DCM mutations do not show a specific correlation with altered Ca2+-sensitivity.
• A proposed mechanism for DCM involves uncoupling of troponin I phosphorylation from Ca2+-sensitivity changes, potentially blunting adrenergic stimulation responses.

Conclusions:

• A pattern is emerging for the functional effects of HCM and DCM mutations.
• HCM mutations likely increase myofibrillar Ca2+-sensitivity, but downstream effects leading to hypertrophy require further investigation.
• DCM mutations may impair signaling pathways, such as the response to adrenergic stimulation, contributing to disease pathogenesis.